Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon

Journal of Nutritional Biochemistry

Volumn 19, Issue 9, 2008, Pages 587-593

  Waldecker, Markus ^a   Kautenburger, Tanja ^a   Daumann, Heike ^a   Busch, Cordula ^a   Schrenk, Dieter ^a  

^a Rheinland Pfälzische Technische Universität Kaiserslautern Landau   (Germany)

Author keywords

Colorectal cancer; Histone deacetylation; HT 29 cells; Inhibition; Polyphenol metabolites; Short chain fatty acids

Indexed keywords

3 (4 HYDROXYPHENYL)PROPIONATE; 3 HYDROXYPHENYLACETATE; 3,4 DIHYDROXYPHENYLACETIC ACID; ACETIC ACID; BUTYRIC ACID; CAFFEIC ACID; CINNAMIC ACID; CINNAMIC ACID DERIVATIVE; COUMARIN DERIVATIVE; HISTONE DEACETYLASE; HYDROCINNAMIC ACID; LYSINE DERIVATIVE; PARA COUMARIC ACID; PHENYLACETIC ACID; POLYPHENOL DERIVATIVE; PROPIONIC ACID; PROPIONIC ACID DERIVATIVE; SHORT CHAIN FATTY ACID;

APOPTOSIS; ARTICLE; ASSAY; CARCINOMA CELL; CELL CULTURE; COLON; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DEGRADATION; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FRUIT; HELA CELL; HUMAN; HUMAN CELL; IC 50; INTESTINE; MALIGNANT TRANSFORMATION; REPORTER GENE; VEGETABLE; WHOLE CELL;

ANTINEOPLASTIC AGENTS; COLON; FATTY ACIDS, VOLATILE; FLAVONOIDS; HELA CELLS; HISTONE DEACETYLASES; HT29 CELLS; HUMANS; PHENOLS; PHENYLACETATES; PHENYLPROPIONATES;

EID: 48649087037     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2007.08.002     Document Type: Article

References (26)

1. Strahl B.D., and Allis C.D. The language of covalent histone modifications. Nature 403 (2000) 41-45
2. Biel M., Wascholowski V., and Giannis A. Epigenetics - an epicenter of gene regulation: histones and histone-modifying enzymes. Angew Chem Int Ed Engl 20 (2005) 3186-3216
3. Jung M. Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem 8 (2001) 505-511
4. Göttlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 17 (2001) 6969-6978
5. Marks P.A., Richon V.M., Miller T., and Kelly W.K. Histone deacetylase inhibitors. Adv Cancer Res 91 (2004) 137-168
6. Mei S., Ho A.D., and Mahlknecht U. Role of histone deacetylase inhibitors in the treatment of cancer. Int J Oncol 6 (2004) 1509-1519
7. Krämer O.H., Göttlicher M., and Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metabol 7 (2001) 294-300
8. Cress W.D., and Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 184 (2000) 1-16
9. Wollowski I., Rechkemmer G., and Pool-Zobel B.L. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr 73 (2001) 451S-455S
10. Boffa L.C., Vidali G., Mann R.S., and Allfrey V.G. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem 253 (1978) 3364-3366
11. Reeves R., and Candido E.P.M. Turnover of histone acetyl groups in cultured cells is inhibited by sodium butyrate. FEBS Lett 91 (1978) 117-120
12. Sealy L., and Chalkley R. The effect of sodium butyrate on histone modification. Cell 14 (1978) 115-121
13. Kiefer J., Beyer-Sehlmeyer G., and Pool-Zobel B.L. Mixtures of SCFA, composed according to physiologically available concentrations in the gut lumen, modulate histone acetylation in human HT29 colon cancer cells. Br J Nutr 96 (2006) 803-810
14. Hinnebusch B.F., Meng S., Wu J.T., Archer S.Y., and Hodin R.A. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr 132 (2002) 1012-1017
15. Jenner A.M., Rafter J., and Halliwell B. Human fecal water content of phenolics: the extent of colonic exposure to aromatic compounds. Free Radical Biol Med 38 (2005) 763-772
16. Lea M.A., and Tulsyan N. Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase. Anticancer Res 15 (1995) 879-883
17. Lea M.A., Randolph V.M., and Hodge S.K. Induction of histone acetylation and growth regulation in erythroleukemia cells by 4-phenylbutyrate and structural analogs. Anticancer Res 19 (1999) 1971-1976
18. Hassan A., Prochasson P., Neely K., Galasinski S., Chandy M., Carrozza M., et al. Function and selectivity of bromodomains in anchoring chromatin-modifying complexes to promoter nucleosomes. Cell 111 (2002) 369-379
19. Lea M.A., Shareef A., Sura M., and des Bordes C. Induction of histone acetylation and inhibition of growth by phenyl alkanoic acids and structurally related molecules. Cancer Chemother Pharmacol 54 (2004) 157-163
20. O'Brien J., Wilson I., Orton T., and Pognan F. Investigation of the AlamarBlue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267 (2000) 5421-5426
21. Kubista M., Akerman B., and Norden B. Characterization of interaction between DNA and 4′,6-diamidino-2-phenylindole by optical spectroscopy. Biochemistry 26 (1987) 4545-4553
22. De Ruijter A.J.M., Van Gennip A.H., Caron H.N., Kemp S., and Van Kuilenburg A.B.P. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochemical J 370 (2003) 737-749
23. Kouraklis G., and Theocharis S. Histone deacetylase inhibitors: a novel target of anticancer therapy. [review]. Oncol Rep 15 (2006) 489-494
24. Iacomino G., Medici M.C., Napoli D., and Russo G.L. Effects of histone deacetylase inhibitors on p55CDC/Cdc20 expression in HT29 cell line. J Cell Biochem 99 (2006) 1122-1131
25. Lea M.A., Ibeh C., Shah N., and Moyer M.P. Induction of differentiation of colon cancer cells by combined inhibition of kinases and histone deacetylases. Anticancer Res 27 (2007) 741-748
26. Newmark H.L., and Young C.W. Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J Cell Biochem (Suppl) 22 (1995) 247-253